Stocktoria
X4 Pharmaceuticals, Inc XFOR
X4 Pharmaceuticals, Inc (XFOR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $35.1M at a -225.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.812 |
| Retained earnings / assets | -2.047 |
| EBIT / assets | -0.299 |
| Equity / liabilities | 1.788 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc | 3/9 | -1.48 | — | — |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
| DTIL | PRECISION BIOSCIENCES INC | 1/9 | -7.2 | — | -50.1% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| SCLX | Scilex Holding Co | 2/9 | — | — | -46.5% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
About X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
FAQ
Is XFOR financially healthy?
X4 Pharmaceuticals, Inc's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does XFOR pay a dividend?
No, X4 Pharmaceuticals, Inc does not currently pay a dividend.
How profitable is XFOR?
In FY2025, X4 Pharmaceuticals, Inc had a net margin of -225.6% and a return on equity of -42.5%.
What is the analyst price target for XFOR?
The average Wall-Street price target for X4 Pharmaceuticals, Inc is $11.75, about 173.9% above the recent price, from 4 analysts.
Is XFOR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on X4 Pharmaceuticals, Inc: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.